Global Premenstrual Syndrome Treatment Market Size, Share, Forecast Report, 2020-2027

For instance, according to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). Thus, increase in prevalence of PMS is anticipated to fuel the demand for drugs, thereby driving the premenstrual syndrome treatment market growth. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.

Premenstrual Syndrome Treatment Market Segmentation

The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type it is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Based on drug type, the premenstrual syndrome treatment market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment, and is estimated to show a significant market growth during the forecast period due to higher adoption of analgesics as first line treatment for the management of PMS.
Analgesics drugs such as ibuprofen, acetaminophen, diclofenac, naproxen are widely used in management symptoms of PMS. These analgesics are generally used to reduce PMS symptoms such as stomach cramps, headache, muscle pain, joint pain and others. These drugs are available over the counter without a prescription but their overuse may cause adverse effects.

According to distribution channel, the premenstrual syndrome treatment is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs over traditional methods, increase in awareness of online providers, and rise in number of internet users.

Asia-Pacific Premenstrual Syndrome Treatment Market

Asia-Pacific presents lucrative opportunities for the key players operating in the premenstrual syndrome treatment market, owing to the growth in awareness regarding premenstrual syndrome treatment, growth in healthcare awareness, and rise in adoption of premenstrual syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, surge in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some other factors such as increase in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, due to high population base is expected to drive the growth of premenstrual syndrome treatment market in this region.
The key players profiled in this report include ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc

Key Benefits for Stakeholders:

• The study provides an in-depth analysis of the premenstrual syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers the Premenstrual syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of all the four major geographical regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global Premenstrual syndrome treatment market growth.

Key Market Segments:

By Drug Type 

• Analgesics
• Antidepressants
• Oral Contraceptives & Ovarian Suppression Agents
• Others

Type

• Prescription
• OTC 

By Distribution Channel 

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers  

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA